Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SUPN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSupernus schedules Q2 2026 earnings release for August 4, 2026
Filed July 22, 2026 · Period ending July 22, 2026 · ~1 min read
Key Changes
-
low
Company will report Q2 2026 financial results after market close on August 4, 2026, followed by a conference call at 4:30 p.m. ET the same day.
Item 2.02 verify on EDGAR →
Summary
Supernus Pharmaceuticals announced it will release second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time the same day to discuss the results.
This is a routine procedural disclosure informing investors when to expect quarterly earnings. The filing contains no financial results or forward-looking guidance—those will be disclosed in the August 4 release and call.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the second quarter of 2026 after the market closes on Tuesday, August 4, 2026. The Company will host a conference call and webcast on Tuesday, August 4, 2026 at 4:30 p.m. E.T. to discuss its second quarter 2026 financial and business results.
The company has scheduled its Q2 2026 earnings release for after market close on August 4, 2026, followed by a conference call and webcast at 4:30 p.m. Eastern Time the same day. This is a routine procedural announcement informing investors when to expect quarterly results.
Event · Exhibit 99.1
Show 2 minor / wording changes
Added in current filing · view on EDGAR →
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.
The company has scheduled the release of its second quarter 2026 financial results for after market close on August 4, 2026. This is a routine quarterly earnings announcement with no financial results disclosed in this filing.
Added in current filing · view on EDGAR →
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss these results.
Management will host a conference call at 4:30 p.m. ET on August 4, 2026 to discuss the quarterly results. The call will be accessible via webcast and dial-in, with a replay available for 60 days afterward.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 23, 2026 · How we verify